Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients

#liquidbiopsy #multiplemyeloma #myeloma

from @MonashUni: Circulating cell-free RNA analysis in multiple myeloma (MM) https://t.co/9UGX1oLPtY Monitoring tumour burden and therapeutic response via circulating tumour DNA and exRNA in MM https://t.co/KkhPrUM30l #biomarker

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. - PubMed - NCBI https://t.co/1bSqxtKq0O.

From the one-of-kind @EagleMyeloma . Pretty obvious. The thing is those two are measuring different processes, one very quantitative in nature (i.e. the number of cells) while the other is more qualitative (the biology of the disease). Both are important.

In a future large #myeloma trial in a hypothetical universe, who would have a tighter confidence interval -- MRD by NGS via @AdaptiveBiotech or circulating tumor DNA and extracellular RNA? #mmsm https://t.co/JL0YN6XS6j

Circulating cell-free tumor DNA as a disease outcome predictor in #MultipleMyeloma? @MonashUni https://t.co/7fASbOAE2e